Bal Pharma has issued an addendum to its earlier notice regarding the Board of Directors meeting scheduled for May 27, 2026. In addition to the previously stated agenda items, the board will now consider a proposal for fund raising through the preferential issue of warrants to promoters. The meeting will be held to discuss the audited financial results for the quarter and financial year ended March 31, 2026, among other key business matters.

Board Meeting Agenda

The board is set to deliberate on a range of significant business items at the May 27 meeting. The following agenda items have been formally listed for consideration:

Trading Window Closure

In accordance with the amended provisions of SEBI (Prohibition of Insider Trading Regulations), 2015 and the company's internal Code of Conduct, the trading window for dealing in securities of Bal Pharma by its designated persons, employees, and their immediate relatives has been closed. The closure is effective from April 1, 2026, and will remain in place until the close of business hours on May 29, 2026—that is, 48 hours after the declaration of the financial results for the financial year ended March 31, 2026.

The intimation has been signed by Shailesh Siroya, Managing Director, on behalf of Bal Pharma Ltd, and has been addressed to the listing compliance managers at both major stock exchanges.

Bal Pharma Limited has notified the stock exchanges of the resignation of Mr. Abdul Basith (Membership No. A70640) from the position of Company Secretary & Compliance Officer of the company, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation takes effect from the close of business hours on Monday, May 11, 2026, and was formally accepted on the same date.

Resignation Details

Mr. Abdul Basith had submitted his resignation letter on March 2, 2026, citing his decision to pursue an alternate career opportunity outside the organisation. In accordance with the company's HR policy, he had requested to be relieved of his responsibilities effective 60 days from the date of the resignation letter. The company accepted the resignation on May 11, 2026, marking the conclusion of his tenure as Company Secretary, Compliance Officer, and Deputy Nodal Officer (IEPF) of Bal Pharma Limited.

The key details of the resignation, as disclosed under the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, are as follows:

Interim Communication Arrangements

Bal Pharma Limited has informed the exchanges that until a formal announcement is made regarding the appointment of a new Company Secretary & Compliance Officer, all communications relating to the company should be directed to secretarial@balpharma.com . The intimation was signed by Shailesh Siroya, Managing Director of Bal Pharma Limited, on May 12, 2026.

The company has also indicated that the necessary statutory filings, including the relevant forms with the Registrar of Companies under the Ministry of Corporate Affairs, will be completed to give effect to the resignation.